Combination medicine for treating cancer

The combination of Clostridium butyricum MIYAIRI 588 with a tyrosine kinase inhibitor enhances antitumor effects and survival rates in cancer patients by leveraging CBM588's ability to withstand digestive fluids and multiply in the intestines, addressing limitations in current chemotherapy treatments.

WO2024241468A1PCT designated stage expired Publication Date: 2024-11-28MIYARISAN PHARMACEUTICAL CO LTD +1

Patent Information

Application Number
PCT/JP2023/019078
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current cancer treatments with chemotherapy, such as anticancer drugs, face limitations in enhancing antitumor effects and improving patient survival rates, particularly when used alone.

Method used

Combining Clostridium butyricum MIYAIRI 588 (CBM588) with a tyrosine kinase inhibitor to enhance antitumor effects, where CBM588 is administered in its spore form to withstand digestive fluids and multiply in the intestines, and the tyrosine kinase inhibitor is selected from a group including EGFR, BCR-ABL, and multikinase inhibitors like regorafenib, potentially with an immune checkpoint inhibitor.

Benefits of technology

This combination significantly reduces tumor volume and increases the survival rate of cancer patients by improving antitumor effects beyond what is achievable with a tyrosine kinase inhibitor alone, with CBM588 being commercially available and showing no side effects over long periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2023019078_28112024_PF_FP_ABST
    Figure JP2023019078_28112024_PF_FP_ABST
Patent Text Reader

Abstract

[Problem] To provide a novel combination medicine for treating cancer. [Solution] This combination medicine for treating cancer contains: a tyrosine kinase inhibitor; and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Combination drugs for cancer treatment

[0001] The present invention relates to a combination drug for treating cancer.

[0002] Probiotics are defined as "live microorganisms that have a positive effect on the health of the host by improving the balance of intestinal flora," and their practical clinical application is being actively attempted in the medical field.

[0003] In addition, probiotics are expected to enhance the therapeutic effects of cancer patients when used in combination with chemotherapy such as anticancer drugs.

[0004] For example, Patent Document 1 describes that the therapeutic effect of an immune checkpoint inhibitor can be enhanced by administering the immune checkpoint inhibitor and Clostridium butyricum Miyairi 588 (FERM BP-2789) to a cancer patient.

[0005] International Publication No. 2021 / 216618

[0006] An object of the present invention is to provide a novel combination drug for cancer treatment.

[0007] The present inventors have surprisingly found that the antitumor effect can be improved by combining Clostridium butyricum MIYAIRI 588 (FERM BP-2789) with a tyrosine kinase inhibitor, and have completed the present invention based on this finding.

[0008] That is, one aspect of the present invention provides a combined drug for cancer treatment comprising a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

[0009] 1 is a graph showing the progression of tumor volume in each group in Test Example 1. 2 is a graph showing the tumor volume at each observation time point (day 4, day 8, day 11, day 15, and day 18) in each group in Test Example 1. 3. Tumor volume 1000 mm in Test Example 1 3 1 is a graph showing a Kaplan-Meier curve with [time taken as an event].

[0010] An embodiment of the present invention will be described below, but the present invention is not limited to the following embodiment.

[0011] In this specification, the range "X to Y" means "X or more and Y or less." Unless otherwise specified, operations and measurements of physical properties are performed under conditions of room temperature (20 to 25°C) and a relative humidity of 40 to 50% RH.

[0012] In this specification, "Clostridium butyricum Miyairi 588 (FERM BP-2789)" will also be referred to simply as "CBM588".

[0013] A first aspect of the present invention is a combined pharmaceutical composition for treating cancer, comprising a tyrosine kinase inhibitor and CBM588 or a culture thereof.

[0014] A second aspect of the present invention is a method for treating cancer, comprising administering to a subject a combination of an effective amount of a tyrosine kinase inhibitor and an effective amount of CBM588 or a culture thereof.

[0015] A third aspect of the present invention is a pharmaceutical composition comprising a tyrosine kinase inhibitor in combination with CBM588 or a culture thereof for use in the treatment of cancer.

[0016] A fourth aspect of the present invention is a pharmaceutical composition for treating cancer, comprising CBM588 or a culture thereof administered in combination with a tyrosine kinase inhibitor.

[0017] A fifth aspect of the present invention is a pharmaceutical composition for treating cancer, comprising a tyrosine kinase inhibitor administered in combination with CBM588 or a culture thereof.

[0018] A sixth aspect of the present invention is a kit for treating cancer, comprising a tyrosine kinase inhibitor and CBM588 or a culture thereof.

[0019] A seventh aspect of the present invention is CBM588 or a culture thereof for use in combination with a tyrosine kinase inhibitor in a method for treating cancer.

[0020] An eighth aspect of the invention is a tyrosine kinase inhibitor for use in conjunction with CBM588 or a culture thereof in a method of treating cancer.

[0021] A ninth aspect of the present invention is the use of a tyrosine kinase inhibitor and / or CBM588 or a culture thereof in a medicament for use in a method of treating cancer comprising administering to a subject a tyrosine kinase inhibitor and CBM588 or a culture thereof.

[0022] In the present invention, by administering a tyrosine kinase inhibitor in combination with CBM588 or a culture thereof, the anti-tumor effect, particularly the effect of reducing tumor volume, can be improved compared to administering a tyrosine kinase inhibitor alone, thereby significantly increasing the survival rate of the subject.

[0023] The tyrosine kinase inhibitor according to the present invention is used in combination with Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof for the treatment of cancer.

[0024] Tyrosine kinase inhibitors are drugs that exert their antitumor effects by inhibiting cellular tyrosine kinases, enzymes involved in many cellular functions, including cell signaling, growth, and division.

[0025] The tyrosine kinase inhibitor according to the present invention is not particularly limited, and any known tyrosine kinase inhibitor can be used. The tyrosine kinase inhibitor is preferably at least one selected from the group consisting of an EGFR tyrosine kinase inhibitor, a c-kit receptor tyrosine kinase inhibitor, a BCR-ABL tyrosine kinase inhibitor, and a multikinase inhibitor, and more preferably a multikinase inhibitor.

[0026] Specific examples of tyrosine kinase inhibitors according to the present invention include, but are not limited to, at least one selected from the group consisting of imatinib, dasatinib, nilotinib, afatinib, erlotinib, osimertinib, gefitinib, axitinib, cabozantinib, sunitinib, sorafenib, pazopanib, regorafenib, and lenvatinib, and more preferably at least one selected from the group consisting of axitinib, cabozantinib, sunitinib, sorafenib, pazopanib, regorafenib, and lenvatinib.

[0027] The Clostridium butyricum MIYAIRI 588 (FERM BP-2789) according to the present invention or a culture thereof is used in combination with a tyrosine kinase inhibitor for the treatment of cancer.

[0028] CBM588 is a spore-forming bacterium that is resistant to various external environments when in the spore state. Therefore, when CBM588 is orally administered to humans or animals in the form of spores, even when it comes into contact with digestive fluids such as gastric acid, intestinal fluid, and bile acid, CBM588 does not completely die but can reach and grow in fermentation sites from the lower small intestine to the large intestine.

[0029] Furthermore, CBM588 is widely available commercially as a probiotic, feed additive, and food product, and has been shown to cause no side effects even when administered to humans or mammals such as livestock over a long period of time, ensuring a high level of safety.

[0030] CBM588 was deposited on May 1, 1981, at the Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently the Patent Organism Depositary, National Institute of Technology and Evaluation, Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818, Japan) under the accession number FERM BP-2789, and was transferred to an international depository organization under the Budapest Treaty on March 6, 1990, where it is deposited under the accession number FERM BP-2789.

[0031] CBM588 is commercially available as a probiotic from Miyarisan Pharmaceutical Co., Ltd., and has no side effects even when administered to humans or animals over the long term. In a preferred embodiment, CBM588 is a probiotic.

[0032] In the present invention, the culture of CBM588 refers to a culture medium in which Clostridium butyrum is cultured, a residue containing bacteria obtained by centrifuging the culture medium, and a dried product of the residue.

[0033] The culture of CBM588 can be obtained by a known method for culturing microorganisms, for example, the method disclosed in Japanese Patent Application Laid-Open No. 08-252088. One embodiment thereof is shown below: CBM588 is cultured in a medium containing 1.0 (w / v)% peptone, 1.0 (w / v)% yeast extract, 1.0 (w / v)% corn starch, and 0.2 (w / v)% precipitated calcium carbonate for 10 minutes. 5 ~10 6 The resulting culture is inoculated to a concentration of 100 cells / mL and allowed to stand at 37°C for 48 hours to obtain a "culture solution of CBM588." The resulting culture solution is then centrifuged (2,000-6,000 g x 10-30 minutes) to separate the "residue containing the bacteria obtained by centrifuging the culture solution." This residue is then dried by air drying or the like at 0-80°C, preferably 10-20°C, for 1-24 hours, preferably 5-18 hours, or by vacuum drying at 0-80°C, preferably 10-20°C, and 0.05-500 Torr (7 Pa-66.7 kPa), preferably 1-100 Torr (133 Pa-13.3 kPa), for 1-24 hours, preferably 2-15 hours, to obtain a "dried residue." Spray drying, freeze drying, or the like may also be used to obtain the dried product.

[0034] The medium used for culturing CBM588 of the present invention may be either a synthetic medium or a natural medium, as long as it contains a carbon source that can be assimilated by CBM588, an appropriate amount of a nitrogen source, inorganic salts, and other nutrients such as vitamins.

[0035] For example, the carbon source used in the medium according to the present invention is not particularly limited as long as it is a carbon source that can be assimilated by CBM588. The carbon source is not necessarily limited to sugars, but considering the growth of the bacterial cells, sugars or sugar-containing materials that can be assimilated by CBM588 are preferably used. Specific examples of usable carbon sources, taking assimilation into consideration, include cellobiose, glucose, fructose, galactose, lactose, maltose, mannose, melibiose, raffinose, salicin, starch, sucrose, trehalose, xylose, dextrin, and molasses. Of these carbon sources, starch, glucose, fructose, sucrose, and molasses are preferred. One or more of the above carbon sources may be selected and used, taking CBM588 into consideration. In this case, the concentration of the carbon source added will vary depending on the type of carbon source used and the composition of the medium other than the carbon source, but is typically 0.5 to 5 (w / v)%, preferably 2 to 4 (w / v)%.

[0036] Examples of nitrogen sources and vitamins include meat extract, peptone, yeast extract, soybean and wheat hydrolysates such as seasoning liquid, soybean powder, milk casein, casamino acids, various amino acids, corn steep liquor, and organic nitrogen compounds such as hydrolysates of other animals, plants, and microorganisms, as well as ammonium salts such as ammonium sulfate. Of these nitrogen sources, peptone, yeast extract, meat extract, corn steep liquor, and seasoning liquid are preferred. One or more of the above-mentioned nitrogen sources and vitamins may be selected and used to improve the growth of CBM588. In this case, the concentration of the nitrogen source added varies depending on the type of bacterial strain and nitrogen source used, the composition of the medium other than the nitrogen source, etc., but when peptone containing a large amount of nitrogen source is used, the concentration is usually 0.5 to 4 (w / v)%, preferably 1 to 3 (w / v)%. When a seasoning liquid or corn steep liquor containing a large amount of nitrogen source and vitamins is used, the concentration is usually 0.5 to 5 (w / v)%, preferably 1 to 4 (w / v)%. Furthermore, when yeast extract or meat extract containing a large amount of vitamins is used, the concentration is usually 0.5 to 4 (w / v)%, preferably 1 to 3 (w / v)%.

[0037] Furthermore, inorganic salts that can be used include one or more selected from phosphates, hydrochlorides, sulfates, butyrates, propionates, acetates, etc. of magnesium, manganese, calcium, sodium, potassium, molybdenum, strontium, boron, copper, iron, tin, zinc, etc. Furthermore, if necessary, antifoaming agents, vegetable oils, surfactants, blood and blood components, drugs such as antibiotics, physiologically active substances such as plant or animal hormones, etc. may be appropriately added to the medium.

[0038] In the present invention, since CBM588 is obligately anaerobic, it is necessary to culture it under anaerobic conditions, for example, without aeration, while aerating nitrogen or carbon dioxide, or by adding a reducing agent to the medium to lower the redox potential. The culture conditions are appropriately selected depending on the composition of the medium and the culture method used, and are not particularly limited as long as they allow CBM588 to grow. Specifically, the culture temperature is usually 20 to 42°C, preferably 35 to 40°C.

[0039] Furthermore, in the present invention, the growth of CBM588 is promoted by neutralizing the acid produced during cultivation with an alkali, so it is preferable to add calcium carbonate to the medium in advance. In this case, the amount of calcium carbonate added is usually 0.1 to 4 (w / v)%, preferably 0.2 to 2.5 (w / v)%. Alternatively, the neutralization step is preferably carried out while controlling the pH of the medium within a set pH range using an aqueous alkali solution such as sodium hydroxide, sodium bicarbonate, sodium carbonate, potassium hydroxide, or potassium carbonate. When an aqueous alkali solution is used, the "set pH" refers to the pH of the medium that is preset during the cultivation period, and the "set pH range" refers to the pH range that is acceptable during the cultivation period, generally expressed as the set pH ± tolerance. According to the present invention, the set pH is usually set within a range of 5.0 to 7.5, preferably 5.5 to 6.5, and the set pH range is set within a range of set pH ± 0.5, preferably set pH ± 0.2.

[0040] In the present invention, the pH of the medium during cultivation is maintained near neutral, preferably 6.5 to 7.5, at the time of inoculation with CBM588. When an alkaline aqueous solution is used, it is preferable to maintain the pH within the set range while gently stirring to prevent oxygen from being mixed in. By controlling the pH at the time of inoculation with CBM588 and during CBM588 growth in this way, it is possible to dramatically increase the bacterial density.

[0041] In the culture according to the present invention, the initial culture concentration of CBM588 is not particularly limited as long as it is within a range in which CBM588 can grow. Specifically, it is usually 10 4 ~10 7 / mL, preferably 10 5 ~10 6 pcs / mL.

[0042] The thus obtained CBM588 culture can be used in combination with a tyrosine kinase inhibitor to enhance the antitumor effect.

[0043] In the present invention, a tyrosine kinase inhibitor and CBM588 or a culture thereof can be used in combination with an immune checkpoint inhibitor for the treatment of cancer.

[0044] Immune checkpoint inhibitors inhibit the function of immune checkpoint receptors or ligands, and examples include antagonists of inhibitory receptors and agonists of costimulatory immune checkpoint receptors.

[0045] The term "antagonist" includes various substances that block receptor activation through binding between a receptor and a ligand, such as substances that bind to a receptor and block the receptor-ligand binding, and substances that bind to a ligand and block the receptor-ligand binding.

[0046] Examples of antagonists against inhibitory immune checkpoints include antagonistic antibodies that bind to inhibitory immune checkpoint molecules (inhibitory receptors or ligands for said receptors), soluble polypeptides designed based on inhibitory immune checkpoint ligands that do not activate receptors, and vectors capable of expressing said polypeptides.

[0047] The immune checkpoint inhibitor according to the present invention is not particularly limited, and any conventionally known immune checkpoint inhibitor can be used. The immune checkpoint inhibitor is preferably at least one selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor, and more preferably a PD-1 inhibitor.

[0048] Specific examples of immune checkpoint inhibitors according to the present invention include, but are not limited to, at least one selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, semipilimab, durvalumab, daclizumab, avelumab, and atezolizumab, and more preferably at least one selected from the group consisting of nivolumab, pembrolizumab, and semipilimab.

[0049] The present invention includes the following embodiments: A combined drug for cancer treatment comprising a tyrosine kinase inhibitor, CBM588, and an immune checkpoint inhibitor; A method for cancer treatment comprising administering to a subject a combination of an effective amount of a tyrosine kinase inhibitor, an effective amount of CBM588 or a culture thereof, and an effective amount of an immune checkpoint inhibitor; A pharmaceutical composition for use in cancer treatment, comprising a combination of a tyrosine kinase inhibitor, CBM588 or a culture thereof, and an immune checkpoint inhibitor; A pharmaceutical composition for cancer treatment, comprising CBM588 or a culture thereof administered in combination with a tyrosine kinase inhibitor and an immune checkpoint inhibitor; A pharmaceutical composition for cancer treatment, comprising CBM588 or a culture thereof, and a tyrosine kinase inhibitor administered in combination with an immune checkpoint inhibitor; A kit for cancer treatment, comprising a tyrosine kinase inhibitor, CBM588 or a culture thereof, and an immune checkpoint inhibitor; CBM588 or a culture thereof for use in conjunction with a tyrosine kinase inhibitor and an immune checkpoint inhibitor in a method for treating cancer; and a tyrosine kinase inhibitor for use in conjunction with CBM588 or a culture thereof and an immune checkpoint inhibitor in a method for treating cancer.

[0050] In the present invention, the type of "cancer" to be treated is not particularly limited. Examples of cancer include oral cancer, pharyngeal cancer, esophageal cancer, gastric cancer, liver cancer, gallbladder cancer, biliary tract cancer, spleen cancer, colon cancer, small intestine cancer, duodenal cancer, colon cancer, colon adenocarcinoma, rectal cancer, pancreatic cancer, liver cancer, bladder cancer, renal cell cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, sarcoma, lymphoma, breast cancer, cervical cancer, uterine cancer, ovarian cancer, testicular cancer, prostate cancer, head and neck cancer, and metastatic cancers thereof. The cancer is preferably at least one selected from the group consisting of colon cancer, metastatic renal cell carcinoma (mRCC), non-small cell lung cancer, melanoma, sarcoma, lymphoma, breast cancer, bladder cancer, cervical cancer, head and neck cancer, liver cancer, gastric cancer, and rectal cancer.

[0051] In the present invention, the term "effective amount" means the amount of an active ingredient (i.e., a tyrosine kinase inhibitor, CBM588, or an immune checkpoint inhibitor) that is at least required to exert the desired effect, such as the treatment of cancer, particularly the improvement of antitumor effect.

[0052] In the present invention, the "subject" is not particularly limited to, but includes mammals and birds, preferably mammals and birds that are or may be affected by cancer. Here, mammals include both primates such as humans, monkeys, gorillas, chimpanzees, and orangutans, as well as non-human mammals such as mice, rats, hamsters, guinea pigs, rabbits, dogs, cats, pigs, cows, horses, sheep, camels, and goats. Birds include chickens, quails, and pigeons. Of these, humans are preferred.

[0053] In the present invention, the tyrosine kinase inhibitor, CBM588 or a culture thereof, and optionally an immune checkpoint inhibitor are administered in combination (concomitant administration) to a subject.

[0054] The combined administration (coadministration) includes simultaneous administration of each component, and sequential administration of each component at predetermined intervals over a treatment period (combination therapy). The route and means of administration of each component administered in combination may be the same or different.

[0055] The dosage and administration method of the tyrosine kinase inhibitor, CBM588 or a culture thereof, and the immune checkpoint inhibitor can be determined appropriately taking into consideration the type of cancer, the symptoms, age, sex, weight, and condition of the subject, etc.

[0056] The dosage of the tyrosine kinase inhibitor is, for example, about 1 to about 2400 mg / kg body weight / day of the active ingredient. The tyrosine kinase inhibitor can be administered daily, every other day, or every few days, divided into 1 to 6 doses per day. The method of administration of the tyrosine kinase inhibitor is not particularly limited, and includes oral administration, intravenous injection, intraarterial injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intramuscular injection, intrathecal injection, and parenteral administration such as transdermal administration or transdermal absorption, with oral administration being preferred. In the examples described below, the dosage of the tyrosine kinase inhibitor is 3 mg / kg body weight / day (5 times a week), and the administration method is oral administration.

[0057] The dosage of CBM588 or a culture thereof is, for example, 0.1 to 1000 mg / kg body weight / day as the active ingredient. CBM588 or a culture thereof can be administered 1 to 6 times a day, every day, every other day, or every few days. The method of administration of CBM588 or a culture thereof is not particularly limited, and examples include oral administration, intravenous injection, intraarterial injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intramuscular injection, intrathecal injection, and parenteral administration such as transdermal administration or transdermal absorption, with oral administration being preferred. In the examples described below, the dosage of CBM588 was approximately 43 mg / kg body weight / day (1 x 10 8 cfu (approximately 1.3 mg) / 100 μL / animal), and the administration method was oral administration.

[0058] The dosage of the immune checkpoint inhibitor is, for example, 0.1 to 20 mg / kg body weight / day of the active ingredient, preferably 2 to 3 mg / kg body weight / day. The immune checkpoint inhibitor can be administered 1 to 6 times daily, every day, every other day, or every few days. The method of administration of the immune checkpoint inhibitor is not particularly limited, and includes oral administration, intravenous injection, intra-arterial injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intramuscular injection, intrathecal injection, and parenteral administration such as transdermal administration or transdermal absorption, and is preferably intraperitoneal administration or intravenous injection. In the Examples described below, the dosage of the immune checkpoint inhibitor is 10 mg / kg body weight / day (five times every three days), and the administration method is intraperitoneal administration.

[0059] In the present invention, the tyrosine kinase inhibitor, CBM588 or a culture thereof, and the immune checkpoint inhibitor may be in the form of a combined pharmaceutical, or each may be in the form of a separate pharmaceutical (or pharmaceutical composition).

[0060] The combination medicine may be in the form of a compounded preparation containing each component in the same composition, or may be in the form of a single package in which each component is prepared separately and suitable for combined administration (i.e., in the form of a kit).

[0061] In the present invention, in addition to the above-mentioned components, additives acceptable for formulation may be further used, such as excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, flavorings, buffers, antioxidants, pH adjusters, binders, thickeners, dispersants, suspending agents, disintegrants, bacteriostatic agents, surfactants, etc.

[0062] In the present invention, the dosage forms of the combination drug, pharmaceutical composition, tyrosine kinase inhibitor, CBM588 or a culture thereof, and immune checkpoint inhibitor are not particularly limited and may be set appropriately, and examples include tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, solutions, suspensions, emulsions, lotions, injections, infusions, topical preparations, suppositories, and patches.

[0063] Embodiments of the present invention are exemplified below. [1] A combination pharmaceutical for cancer treatment comprising a tyrosine kinase inhibitor and Clostridium butyricum Miyairi 588 (FERM BP-2789) or a culture thereof. [2] The combination pharmaceutical for cancer treatment according to [1], wherein the Clostridium butyricum Miyairi 588 is a live bacterium. [3] The combination pharmaceutical for cancer treatment according to [1] or [2], wherein the tyrosine kinase inhibitor is at least one selected from the group consisting of an EGFR tyrosine kinase inhibitor, a c-kit receptor tyrosine kinase inhibitor, a BCR-ABL tyrosine kinase inhibitor, and a multikinase inhibitor. [4] The combination pharmaceutical for cancer treatment according to any one of [1] to [3], wherein the tyrosine kinase inhibitor is at least one selected from the group consisting of imatinib, dasatinib, nilotinib, afatinib, erlotinib, osimertinib, gefitinib, axitinib, cabozantinib, sunitinib, sorafenib, pazopanib, regorafenib, and lenvatinib. [5] The combination pharmaceutical for cancer treatment according to any one of [1] to [4], further comprising an immune checkpoint inhibitor. [6] The combination pharmaceutical for cancer treatment according to [5], wherein the immune checkpoint inhibitor is at least one selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. [7] The combination drug for cancer treatment according to [5] or [6], wherein the immune checkpoint inhibitor is at least one selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, semipilimab, durvalumab, daclizumab, avelumab, and atezolizumab. [8] The combination drug for cancer treatment according to any of [1] to [7], wherein the cancer is at least one selected from the group consisting of colorectal cancer, metastatic renal cell carcinoma (mRCC), non-small cell lung cancer, melanoma, sarcoma, lymphoma, breast cancer, bladder cancer, cervical cancer, head and neck cancer, liver cancer, gastric cancer, and rectal cancer.[9] A method for treating cancer, comprising administering to a subject a combination of an effective amount of a tyrosine kinase inhibitor and an effective amount of Clostridium butyricum Miyairi 588 (Clostridium butyricum MIYAIRI 588, FERM BP-2789) or a culture thereof.

[10] A pharmaceutical composition for use in treating cancer, comprising a combination of a tyrosine kinase inhibitor and Clostridium butyricum Miyairi 588 (Clostridium butyricum MIYAIRI 588, FERM BP-2789) or a culture thereof.

[11] A pharmaceutical composition for cancer treatment, comprising Clostridium butyricum Miyairi 588 (FERM BP-2789) or a culture thereof, administered in combination with a tyrosine kinase inhibitor.

[12] A pharmaceutical composition for cancer treatment, comprising Clostridium butyricum Miyairi 588 (FERM BP-2789) or a culture thereof, administered in combination with a tyrosine kinase inhibitor.

[13] A cancer treatment kit comprising a tyrosine kinase inhibitor and Clostridium butyricum Miyairi 588 (FERM BP-2789) or a culture thereof.

[14] Clostridium butyricum Miyairi 588 (FERM BP-2789) or a culture thereof for use together with a tyrosine kinase inhibitor in a cancer treatment method.

[15] A tyrosine kinase inhibitor for use in a method for treating cancer, together with Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

[16] Use of a tyrosine kinase inhibitor and / or Clostridium butyricum Miyairi 588 (Clostridium butyricum MIYAIRI 588, FERM BP-2789) or a culture thereof in a medicament for use in a method for treating cancer, comprising administering a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof to a subject.

[0064] The present invention will be described below using specific examples, but the present invention is not limited to these examples. Unless otherwise specified, the operations were carried out at room temperature (25° C.).

[0065] Animal experiments using mice were conducted with the approval of the Animal Experiment Committee of the Osaka International Cancer Institute (approval number: 23022121).

[0066] Test Example 1 BALB / c mice (7 weeks old, male / female, purchased from CLEA Japan, SPF) were subjected to a 7-day quarantine and acclimation period, and after confirming that all mice were in good health and had not lost weight, they were used in the test. The mice were reared in a 12-hour lighting environment with a temperature of 20-26°C and humidity of 30-70%, and were allowed to have free access to food and water.

[0067] Mouse colon cancer cell line (CT26) 1 x 10 6The tumors were collected, mixed with 80 μL of high-concentration Matrigel, and injected subcutaneously into mice. Starting 21 days after subcutaneous injection or when tumor formation was confirmed by palpation, whichever came first, a tyrosine kinase inhibitor (TKI), an immune checkpoint inhibitor (ICI), or Clostridium butyricum MIYAIRI 588 (FERM BP-2789) was administered to the tumors in five groups: TKI group, TKI + CBM group, ICI group, TKI + ICI group, and TKI + ICI + CBM group (n = 7 (TKI group, TKI + CBM group) and n = 6 (ICI group, TKI + ICI group, TKI + ICI + CBM group)). In the control group (n=7), TKI, ICI and CBM588 were not administered.

[0068] The mice used in the study were euthanized as a humane endpoint 28 days after the start of administration, or when the tumor minor axis reached 10 mm or the tumor mass reached 10% of the body weight. 3 Mice exceeding this were excluded.

[0069] Details of the drugs used and their dosage are shown below. TKI: Regorafenib (#R0142, Tokyo Chemical Industry Co., Ltd.) 30 μg / g, 100 μL (maximum volume 1000 μL) once a day for 9 days, orally administered. ICI: Anti-CD279 antibody (J43; BE-00332, Iwai Chemicals Co., Ltd.) 5 μg / g, 100 μL (maximum volume 1600 μL) every 3 days, intraperitoneally administered (continued until the end of the observation period). CBM: MiyaBM original powder (Miyarisan Pharmaceutical Co., Ltd.) 1 x 10 8 cfu / 100 μL, 100 μL per dose was orally administered three times a week.

[0070] On the 4th, 8th, 11th, 15th and 18th days after the start of administration, the tumor minor axis (mm) and tumor major axis (mm) were measured, and the tumor volume was calculated using the following formula: Tumor volume (mm 3 ) = 1 / 2 × tumor short diameter × tumor short diameter × tumor long diameter.

[0071] The results are shown in Figures 1 and 2.

[0072] As shown in Figures 1 and 2, it can be seen that the combination of a tyrosine kinase inhibitor and CBM588 can suppress an increase in tumor volume.

[0073] In addition, tumor volume 1000 mm 3 The Kaplan-Meier curve with * as an event is shown in Figure 3. As shown in Figure 3, the log-rank test shows that the TKI+CBM group exhibits a significantly higher progression-free rate than the control group and the TKI group.

Claims

1. A combination drug for cancer treatment comprising a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

2. The combination drug for cancer treatment according to claim 1, wherein the Clostridium butyricum miyairi 588 is a live bacterium.

3. The combination drug for cancer treatment according to claim 1, wherein the tyrosine kinase inhibitor is at least one selected from the group consisting of EGFR tyrosine kinase inhibitors, c-kit receptor tyrosine kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, and multikinase inhibitors.

4. The combination drug for cancer treatment according to claim 3, wherein the tyrosine kinase inhibitor is at least one selected from the group consisting of imatinib, dasatinib, nilotinib, afatinib, erlotinib, osimertinib, gefitinib, axitinib, cabozantinib, sunitinib, sorafenib, pazopanib, regorafenib, and lenvatinib.

5. The combination pharmaceutical for cancer treatment according to claim 1, further comprising an immune checkpoint inhibitor.

6. The combination drug for cancer treatment according to claim 5, wherein the immune checkpoint inhibitor is at least one selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor.

7. The combination drug for cancer treatment according to claim 6, wherein the immune checkpoint inhibitor is at least one selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, semipilimab, durvalumab, daclizumab, avelumab, and atezolizumab.

8. The combination drug for cancer treatment according to claim 1, wherein the cancer is at least one selected from the group consisting of colorectal cancer, metastatic renal cell carcinoma (mRCC), non-small cell lung cancer, melanoma, sarcoma, lymphoma, breast cancer, bladder cancer, cervical cancer, head and neck cancer, liver cancer, gastric cancer, and rectal cancer.

9. A method for treating cancer, comprising administering to a subject a combination of an effective amount of a tyrosine kinase inhibitor and an effective amount of Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

10. A pharmaceutical composition comprising a combination of a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof for use in the treatment of cancer.

11. A pharmaceutical composition for cancer treatment comprising Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof administered in combination with a tyrosine kinase inhibitor.

12. A pharmaceutical composition for treating cancer, comprising a tyrosine kinase inhibitor administered in combination with Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

13. A kit for treating cancer, comprising a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

14. Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof for use together with a tyrosine kinase inhibitor in a method for treating cancer.

15. A tyrosine kinase inhibitor for use together with Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof in a method for treating cancer.

16. Use of a tyrosine kinase inhibitor and / or Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof in a medicament for use in a method for treating cancer comprising administering to a subject a tyrosine kinase inhibitor and Clostridium butyricum MIYAIRI 588 (FERM BP-2789) or a culture thereof.

Citation Information

Patent Citations

  • Method for culturing bacteria in clostridium

    JP1996252088A

  • Growth inhibitor of colon cancer cells

    JP2009269836A

  • Method for treating liver cancer with combined use of REIC / dkk-3 gene and Anti-tumor agent

    WO2021020554A1

  • Compositions and methods comprising clostridium butyricum for the treatment of cancer

    WO2021216618A1

Cited By

  • Medicine for treating EGFR mutation non-small cell lung cancer meningeal metastasis, application, medicine box and preparation method of medicine

    CN121177212A

  • A drug, application, kit and preparation method of the drug for treating EGFR mutant non-small cell lung cancer meningeal metastasis

    CN121177212B